All News

Our longtime editor-in-chief offers advice to his successor while discussing the news and education CURE magazine provides for patients with cancer, families and caregivers.

When my spouse and I both faced cancer, maintaining a positive attitude, seeking support, listening empathetically and managing stress helped us through it.

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ breast cancer using circulating tumor DNA.

Dr. Kandace P. McGuire discusses how targeted axillary staging differs from traditional methods of staging in patients undergoing breast cancer treatment.

RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according to study findings.

Kelly Grosklags discusses how oncologists can guide patients in shared decision-making while managing expectations following a breast cancer diagnosis.

This month’s Research Spotlight highlights significant advancements in pancreatic cancer research and patient support.

The first patient has been enrolled in the phase 3 PROSTATE-IQ trial being conducted in men with prostate cancer recurrence following a prostatectomy.

Life-threatening lung cancer has taught me many valuable lessons and made my new normal so fulfilling.

JAK inhibitor treatment is associated with a reduction in risk of thromboembolic events for patients with myeloproliferative neoplasms.

Treatment with pimitespib was associated with stable disease in two-thirds of patients with advanced gastrointestinal stromal tumors.

Dr. Joseph Mikhael discusses early signs, treatments and supportive care for multiple myeloma in an interview with CURE.

For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes.

As a cancer survivor, I overcame alcohol addiction and urge others to seek support, safe detox and sobriety to improve their treatment and recovery.

Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.

CURE magazine's outgoing editor-in-chief, Dr. Debu Tripathy, reflects on 18 years of advances in cancer care, the impact of AI and the evolving future of oncology treatment.

Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing mutation testing for treatment decisions.

Circulating tumor DNA may be a prognostic biomarker for relapse and early recurrence detection in resected early-stage biliary tract cancer.

The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric and gastroesophageal junction cancers.

177Lu-edotreotide shows potential to extend progression-free survival in patients with grade 1 or 2 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

New advancements in cancer treatment are reducing the need for radical surgeries, offering organ-sparing therapies and enhancing survivorship care and support for patients.

Living with follicular lymphoma, I challenge common misconceptions about cancer, highlighting the unique and varied experiences of patients with cancer.

Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in patients with BRCA1/2 mutations.

Calquence plus Venclexta with or without Gazyva significantly improved progression-free survival in patients with untreated CLL.

Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical benefits versus chemotherapy.

The FDA has approved Imfinzi for some adults with limited-stage small cell lung cancer.

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer.